The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Background: Trials show that weight loss interventions improve biomarkers of non-alcoholic fatty liver disease (NAFLD), but it is unclear if a dose-response relationship exists.

Objective: We aimed to quantify the dose-response relationship between the magnitude of weight loss and improvements in NAFLD.

Methods: Nine databases and trial registries were searched until October 2020.

Serum calcification propensity predicts all-cause mortality in predialysis CKD.

Medial arterial calcification is accelerated in patients with CKD and strongly associated with increased arterial rigidity and cardiovascular mortality. Recently, a novel in vitro blood test that provides an overall measure of calcification propensity by monitoring the maturation time (T50) of calciprotein particles in serum was described. We used this test to measure serum T50 in a prospective cohort of 184 patients with stages 3 and 4 CKD, with a median of 5.